See the DrugPatentWatch profile for Galafold
Who holds the Galafold (migalastat) patents, and what are they trying to protect?
Galafold is the brand name for migalastat, a therapy for certain Fabry disease patients. Patent protection typically covers the drug substance, manufacturing process, and approved uses (including specific patient populations and dosing regimens). The exact patent holders and the specific claims that protect “Galafold” depend on country and the patent family used in that market.
When do Galafold patents expire (by country)?
Patent expiry for Galafold varies by jurisdiction because patents are filed at different times and have different term rules (including adjustments and extensions). To determine the likely end of exclusivity in a specific country, you need:
- The patent family numbers for migalastat in that country
- Whether any term extensions or supplementary protection exist
- Whether regulatory exclusivity (not the same as patent life) adds additional market protection
Without a specific country (e.g., US vs EU vs UK vs Canada vs Japan), I can’t give an accurate expiry date.
What counts as a “patent” versus “exclusivity” for Galafold?
Even after a patent expires, a product can still be blocked by other forms of protection, such as:
- Additional patents in the same family (e.g., manufacturing or method-of-use claims)
- Regulatory data/exclusivity periods
- Patent litigation outcomes (for example, if a generic/biosimilar applicant is challenged)
This matters because people often search “Galafold patent expiry” when they actually want “when competitors can launch.”
Are generics or competitors allowed right after Galafold’s patents expire?
Competitors generally need to navigate both:
- Patent status (whether any enforceable claims still cover their product or process)
- Regulatory approval pathways (which can be affected by exclusivity and labeling)
If patents are still in force or litigation blocks launch, market entry can be delayed beyond the earliest expiry date.
Why are people searching “Galafold patent” alongside “generic” or “ANDA”?
That search pattern usually points to whether a generic or follow-on product can be approved and marketed. Outcomes depend on:
- The specific patents listed as blocking (often based on the Orange Book in the US, or equivalent registries elsewhere)
- Whether patents are found invalid/infringed, or if launch is stayed by court decisions or settlements
What can you do if you want the exact Galafold patent numbers and deadlines?
If you share:
1) the country/region you care about, and
2) whether you want drug substance, method-of-use, or manufacturing-process patents,
I can help you identify the right patent records to check for that market (and what to look for on each document).
Quick clarification
Which jurisdiction do you mean by “Galafold patent” (US, EU, UK, Canada, Japan, other)?